Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:08 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors
NCT06372574 · Genentech, Inc. · PHASE1 · withdrawn · last registry update 2024-09-03 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “GO44669 study has been withdrawn due to an internal Sponsor decision. The decision was not due to any safety or efficacy concerns with the study drug.” | – | Registry record, Genentech, Inc. |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL6R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-06-17Results posted on the registry: Cambridge University Hospitals NHS Foundation Trust, Rituximab + Infliximab (NCT05168475)
- 2025-06-17Also stopped (terminated): Cambridge University Hospitals NHS Foundation Trust, Rituximab + Infliximab (NCT05168475)
- 2025-06-12Results posted on the registry: Assistance Publique - Hôpitaux de Paris, Sarilumab (NCT04324073)
- 2025-06-12Results posted on the registry: Assistance Publique - Hôpitaux de Paris, Tocilizumab (NCT04331808)
- 2025-06-05Results posted on the registry: University of Chicago, Tocilizumab + Tocilizumab (NCT04479358)
- 2025-05-28Also stopped (terminated): Memorial Sloan Kettering Cancer Center, Tocilizumab (NCT04377659)
- 2025-03-04Also stopped (withdrawn): University of Florida, Satralizumab (NCT05727657)
- 2025-02-28Results posted on the registry: Hoffmann-La Roche, Satralizumab (NCT04963270)
- 2025-02-28Also stopped (terminated): Hoffmann-La Roche, Satralizumab (NCT04963270)
- 2025-02-18Phase 3 first posted: Insel Gruppe AG, University Hospital Bern, Prednisone + Prednisone (NCT06833411)
- 2025-02-10Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Tocilizumab (RoActemra®, 20 mg/mL). + Placebo (NaCl 0.9%) (NCT06818266)
- 2025-02-04Also stopped (terminated): National Cancer Institute (NCI), Tocilizumab (NCT04370834)
- 2025-01-22Results posted on the registry: Hoffmann-La Roche, Satralizumab 120 mg (NCT05269667)
- 2025-01-22Also stopped (terminated): Hoffmann-La Roche, Satralizumab 120 mg (NCT05269667)
- 2024-12-27Results posted on the registry: Hoffmann-La Roche, satralizumab + azathioprine (AZA) (NCT04660539)
- 2024-12-18Results posted on the registry: Hoffmann-La Roche, Mosunetuzumab + Polatuzumab Vedotin (NCT03677141)
- 2024-12-17Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), sarilumab (NCT03770273)
- 2024-12-10Phase 3 first posted: Beijing VDJBio Co., LTD., Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection (NCT06726096)
- 2024-12-09Results posted on the registry: Hoffmann-La Roche, RO7119929 + Tocilizumab (NCT04338685)
- 2024-11-01Also stopped (terminated): University of Zurich, Actemra (NCT04652258)
- 2024-10-23Phase 3 first posted: Duke University, TNFi (Tumor Necrosis Factor inhibitor) medication + Abatacept (NCT06654882)
- 2024-10-15Results posted on the registry: Sanofi, Sarilumab (NCT02776735)
- 2024-10-09Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), lulizumab pegol + antithymocyte globulin (rabbit) (NCT04066114)
- 2024-10-09Results posted on the registry: NYU Langone Health, Ipilimumab + Nivolumab (NCT03999749)
- 2024-10-08Results posted on the registry: Celltrion, CT-P47 + EU-approved RoActemra (NCT05489224)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision